<code id='5905BF3E0E'></code><style id='5905BF3E0E'></style>
    • <acronym id='5905BF3E0E'></acronym>
      <center id='5905BF3E0E'><center id='5905BF3E0E'><tfoot id='5905BF3E0E'></tfoot></center><abbr id='5905BF3E0E'><dir id='5905BF3E0E'><tfoot id='5905BF3E0E'></tfoot><noframes id='5905BF3E0E'>

    • <optgroup id='5905BF3E0E'><strike id='5905BF3E0E'><sup id='5905BF3E0E'></sup></strike><code id='5905BF3E0E'></code></optgroup>
        1. <b id='5905BF3E0E'><label id='5905BF3E0E'><select id='5905BF3E0E'><dt id='5905BF3E0E'><span id='5905BF3E0E'></span></dt></select></label></b><u id='5905BF3E0E'></u>
          <i id='5905BF3E0E'><strike id='5905BF3E0E'><tt id='5905BF3E0E'><pre id='5905BF3E0E'></pre></tt></strike></i>

          hotspot

          hotspot

          author:entertainment    Page View:6365
          A sign of AdventHealth on its building in Orlando, Florida — coverage from STAT
          Adobe

          A lawsuit between a large hospital system and a dominant vendor that works for health insurance companies is getting a lot more heated — with one party calling the other an “economic parasite.”

          The suit, between nonprofit hospital giant AdventHealth and MultiPlan, is now even attracting rare interest from the nation’s biggest hospital lobbyists.

          advertisement

          The new, highly detailed legal filings also come right as MultiPlan and more than a dozen of the largest tax-exempt, nonprofit hospital systems are wooing investors at the J.P. Morgan Healthcare Conference. AdventHealth did not attend this year’s conference, but did so last year.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Longer MASH drug regimen improved liver, Akero study finds
          Longer MASH drug regimen improved liver, Akero study finds

          AdobeAkeroTherapeuticssaidMondaythatextendingtreatmentwithitsexperimentaldrugfortheliverdiseaseknown

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Medicare drug price negotiation hearing pits pharma v Biden admin

          AdobeTRENTON,N.J.—PharmaindustrygiantsincludingBristolMyersSquibb,Johnson&Johnson,Novartis,andNo